标题
Histone deacetylase inhibitors in hematological malignancies and solid tumors
作者
关键词
Histone deacetylase inhibitors, Cancer, Apoptosis, Cell cycle arrest, Angiogenesis, DNA damage and repair
出版物
ARCHIVES OF PHARMACAL RESEARCH
Volume 38, Issue 6, Pages 933-949
出版商
Springer Nature
发表日期
2015-02-04
DOI
10.1007/s12272-015-0571-1
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Compromised Structure and Function of HDAC8 Mutants Identified in Cornelia de Lange Syndrome Spectrum Disorders
- (2014) Christophe Decroos et al. ACS Chemical Biology
- A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
- (2014) Michinori Ogura et al. BRITISH JOURNAL OF HAEMATOLOGY
- Suberoylanilide hydroxamic acid suppresses inflammation-induced neovascularization
- (2014) Hongyan Zhou et al. CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY
- Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer
- (2014) Panagiotis A. Konstantinopoulos et al. GYNECOLOGIC ONCOLOGY
- Disruption of autophagy by the histone deacetylase inhibitor MGCD0103 and its therapeutic implication in B-cell chronic lymphocytic leukemia
- (2014) V El-Khoury et al. LEUKEMIA
- The Histone Deacetylase Inhibitor, Vorinostat, Represses Hypoxia Inducible Factor 1 Alpha Expression through Translational Inhibition
- (2014) Darren M. Hutt et al. PLoS One
- Histone deacetylase 6 and cytoplasmic linker protein 170 function together to regulate the motility of pancreatic cancer cells
- (2014) Dengwen Li et al. Protein & Cell
- Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer - overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression
- (2013) Berit Maria Müller et al. BMC CANCER
- HDAC Up-Regulation in Early Colon Field Carcinogenesis Is Involved in Cell Tumorigenicity through Regulation of Chromatin Structure
- (2013) Yolanda Stypula-Cyrus et al. PLoS One
- Multi-targeted hybrids based on HDAC inhibitors for anti-cancer drug discovery
- (2012) Seung-Yong Seo ARCHIVES OF PHARMACAL RESEARCH
- QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: A case report and review of the literature
- (2012) Donald R. Lynch Jr et al. Cardiology Journal
- HDAC11 is a novel drug target in carcinomas
- (2012) Hedwig E. Deubzer et al. INTERNATIONAL JOURNAL OF CANCER
- HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins
- (2012) Kwang Hwa Jung et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy
- (2012) Bertrand Coiffier et al. JOURNAL OF CLINICAL ONCOLOGY
- Histone Deacetylase in Chronic Lymphocytic Leukemia
- (2012) J.C. Wang et al. ONCOLOGY
- Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer
- (2012) Missak Haigentz et al. ORAL ONCOLOGY
- HDAC1 Inactivation Induces Mitotic Defect and Caspase-Independent Autophagic Cell Death in Liver Cancer
- (2012) Hong Jian Xie et al. PLoS One
- Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS)
- (2011) Amanda Cashen et al. ANNALS OF HEMATOLOGY
- Histone deacetylase inhibitor sodium butyrate enhances cellular radiosensitivity by inhibiting both DNA nonhomologous end joining and homologous recombination
- (2011) Miglena Koprinarova et al. DNA REPAIR
- Analysis of apoptosis regulatory genes altered by histone deacetylase inhibitors in chronic lymphocytic leukemia cells
- (2011) Alba Pérez-Perarnau et al. Epigenetics
- Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
- (2011) Mark Kirschbaum et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial Tumors
- (2011) Giuseppe Giaccone et al. JOURNAL OF CLINICAL ONCOLOGY
- Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung
- (2011) Yoshihiro Minamiya et al. LUNG CANCER
- Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes
- (2011) Marcus Bantscheff et al. NATURE BIOTECHNOLOGY
- Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC
- (2011) Karl Quint et al. VIRCHOWS ARCHIV
- A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours
- (2010) U Lassen et al. BRITISH JOURNAL OF CANCER
- research paper: Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia
- (2010) Daniel Antunes Moreno et al. BRITISH JOURNAL OF HAEMATOLOGY
- HDAC5 and HDAC9 in Medulloblastoma: Novel Markers for Risk Stratification and Role in Tumor Cell Growth
- (2010) T. Milde et al. CLINICAL CANCER RESEARCH
- Macrocyclic Histone Deacetylase Inhibitors
- (2010) Sandra C. Mwakwari et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours
- (2010) Helen J. Mackay et al. EUROPEAN JOURNAL OF CANCER
- Inside HDAC with HDAC inhibitors
- (2010) Philippe Bertrand EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin's lymphoma
- (2010) Heiner Adams et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin
- (2010) Akiko Hayashi et al. INTERNATIONAL JOURNAL OF CANCER
- Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma
- (2010) Sean J. Whittaker et al. JOURNAL OF CLINICAL ONCOLOGY
- Vorinostat (NSC# 701852) in Patients with Relapsed Non-small Cell Lung Cancer: A Wisconsin Oncology Network Phase II Study
- (2010) Anne M. Traynor et al. Journal of Thoracic Oncology
- Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma
- (2010) Suresh S. Ramalingam et al. Journal of Thoracic Oncology
- Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304)
- (2010) Gregory A. Otterson et al. Journal of Thoracic Oncology
- Chemical phylogenetics of histone deacetylases
- (2010) James E Bradner et al. Nature Chemical Biology
- Apoptosis in cancer: Key molecular signaling pathways and therapy targets
- (2009) Claudia Burz et al. ACTA ONCOLOGICA
- Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)
- (2009) L. R. Molife et al. ANNALS OF ONCOLOGY
- Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862)
- (2009) Deborah Bradley et al. CANCER
- Dual Degradation of Aurora A and B Kinases by the Histone Deacetylase Inhibitor LBH589 Induces G2-M Arrest and Apoptosis of Renal Cancer Cells
- (2009) T.-L. Cha et al. CLINICAL CANCER RESEARCH
- Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
- (2009) Richard L. Piekarz et al. JOURNAL OF CLINICAL ONCOLOGY
- High Histone Deacetylase 7 (HDAC7) Expression Is Significantly Associated with Adenocarcinomas of the Pancreas
- (2008) Mehdi Ouaïssi et al. ANNALS OF SURGICAL ONCOLOGY
- An HDAC inhibitor, trichostatin A, induces a delay at G2/M transition, slippage of spindle checkpoint, and cell death in a transcription-dependent manner
- (2008) Eun Joo Noh et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors
- (2008) Nagma Khan et al. BIOCHEMICAL JOURNAL
- Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer
- (2008) Florian R Fritzsche et al. BMC CANCER
- Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy
- (2008) W Weichert et al. BRITISH JOURNAL OF CANCER
- Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo
- (2008) W. Weichert et al. CLINICAL CANCER RESEARCH
- A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors
- (2008) N. L. Steele et al. CLINICAL CANCER RESEARCH
- A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study
- (2008) T. H. Luu et al. CLINICAL CANCER RESEARCH
- Histone Deacetylase 8 in Neuroblastoma Tumorigenesis
- (2008) I. Oehme et al. CLINICAL CANCER RESEARCH
- A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study
- (2008) Susan C. Modesitt et al. GYNECOLOGIC ONCOLOGY
- Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma
- (2008) L Marquard et al. HISTOPATHOLOGY
- Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)
- (2008) Robert P. Whitehead et al. INVESTIGATIONAL NEW DRUGS
- Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer
- (2008) Johan Vansteenkiste et al. INVESTIGATIONAL NEW DRUGS
- Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis
- (2008) Wilko Weichert et al. LANCET ONCOLOGY
- MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo
- (2008) M. Fournel et al. MOLECULAR CANCER THERAPEUTICS
- The SIRT1 Deacetylase Suppresses Intestinal Tumorigenesis and Colon Cancer Growth
- (2008) Ron Firestein et al. PLoS One
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started